Abstracts

Filters

Clear Filters
All Days Sun, Sep 28 Mon, Sep 29 Tue, Sep 30 Wed, Oct 01

Sunday, September 28

3:20 PM - 3:30 PM PT

105 - Use of Gadolinium Nanoparticles as Radiosensitizers for Brain Metastases: Results from the Phase 2 Multicentric Randomized Trial (NANORAD2)
Speaker: Verry, Camille, MD - Centre Hospitalier Universitaire Grenoble Alpes, Grenoble
3:20 PM - 3:30 PM PT

112 - Efficacy and Safety of Short-Course Radiotherapy Followed By Sequential Chemotherapy and AK104 in Locally Advanced Rectal Cancer: Results from a Prospective, Multicenter Phase II Trial
Speaker: Xu, Tongzhen, MD - Chinese Academy of Medical Science, Bejing, Beijing
3:20 PM - 3:30 PM PT

119 - Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial
Speaker: Niazi, Tamim, MD - McGill University, Montreal, QC
3:20 PM - 3:30 PM PT

126 - A Real-World Comparison of Moderated Hypofractionated Radiotherapy and Conventional Fractionated Radiotherapy in Cervical Cancer
Speaker: Zeng, Zheng, MD - Peking Union Medical College Hospital, Beijing, Beijing
3:20 PM - 3:30 PM PT

132 - Consolidative Radiotherapy with Osimertinib in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: Long-Term Local and Intracranial Control Results from a Phase II Trial
Speaker: Sampath, Sagus, MD - City of Hope Medical Center, Duarte, CA
3:20 PM - 3:30 PM PT

139 - Genomic and Transcriptomic Profiling of Radiation Resistant, Locally Recurrent Prostate Cancer
Speaker: Neilsen, Beth, MD, PhD - University of California Los Angeles, Los Angeles, CA
3:30 PM - 3:40 PM PT

106 - Prospective Interventional Study Investigating the Neurocognitive Effects and Quality of Life (QOL) in Patients with Brain Metastases, Comparing Hippocampal Avoidance Whole-Brain Radiation Therapy (HA
Speaker: Das, Souvik Sankar - Chittaranjan National Cancer Institute, Kolkata, West Benga
3:30 PM - 3:35 PM PT

120 - 5-Year Results of a Prospective, Non-Randomized Controlled Study: Comparison of the Efficacy and Safety of ADT + Docetaxel vs. ADT + Novel Hormone Therapy in High Gleason Score Non-Metastatic Prostate
Speaker: Ma, Mingwei, MD - Peking University First Hospital, Beijing, Beijing
3:30 PM - 3:40 PM PT

133 - First-Line EGFR-TKIs Combined with Primary-Focus Radiotherapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): A Real-World Retrospective Study
Speaker: Li, Yan, MD - West China Hospital of Sichuan University, Chengdu, Sichuan
3:30 PM - 3:40 PM PT

Discussant
Speaker: Olsen, Jeffrey, MD - University of Colorado School of Medicine, Aurora, CO
3:30 PM - 3:40 PM PT

Discussant
Speaker: Mowery, Yvonne, MD, PhD, BS - University of Pittsburgh Medical Center, Pittsburgh, PA
3:30 PM - 3:40 PM PT

Discussant
Speaker: Klopp, Ann, MD, PhD - MD Anderson Cancer Center, Houston, TX